Related Experiment Videos

Association between dexmedetomidine administration and 28-day mortality in critically ill patients with

Songmei Guan¹, Congcong Lv^2,3, Shigang Duan⁴

¹Department of Pharmacy, Zhejiang Provincial People's Hospital Bijie Hospital (The First People's Hospital of Bijie), Bijie, Guizhou, China.

Frontiers in Pharmacology

|July 10, 2026

Abstract

Background:

Ventilator-associated pneumonia (VAP) is a frequent intensive care unit (ICU) complication linked to prolonged ventilation, extended ICU and hospital stays, increased costs, and higher mortality. Current guidelines recommend light sedation with dexmedetomidine (DEX) or propofol for ventilated adults. Although DEX has shown anti-inflammatory effects in animal models, its impact on VAP outcomes remains unclear. This study aims to investigate the association between DEX administration and 28-day mortality in patients with VAP.

Methods:

This retrospective cohort study enrolled VAP patients from the Medical Information Mart for Intensive Care (MIMIC) (version 3.0) database, categorized into DEX-treated and non-DEX groups during ICU admission. The primary outcome was 28-day mortality. Secondary outcomes included ICU, in-hospital mortality. Kaplan-Meier (KM) survival curves with log-rank tests and Cox proportional hazards models evaluated the association between DEX use and mortality outcomes. To adjust for baseline differences, 1:1 propensity score matching (PSM) was applied. Interaction and subgroup analyses further examined result consistency.

Results:

Data from 1,753 patients were analyzed, comprised 901 in the DEX group and 852 in the non-DEX group. The analysis of KM curves revealed a significantly lower 28-day mortality rate in the DEX group compared to the non-DEX group. After adjusting for multiple confounding factors, the Cox regression model demonstrated a significant protective impact of DEX-use on the risk of 28-day mortality in patients with VAP, with hazard ratios (HR) of 0.54 (95% confidence interval (CI): 0.43-0.67, p < 0.001). PSM analysis confirmed these results, showing HR of 0.81 (95% CI: 0.65-0.99, p = 0.044). No interactions were observed between DEX-use and 28-day mortality across stratified variables.

Conclusion:

DEX administration during the ICU stays was associated with improved outcomes in critically ill patients with VAP. The results need to be verified in randomized controlled trials.

Keywords:

MIMIC-IV database dexmedetomidine intensive care unit mortality ventilator-associated pneumonia

Related Concept Videos

Parenteral Anesthetics: Overview

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.

Acute Respiratory Failure-II

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

Acute Respiratory Failure-III

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Articles linked to this work by shared authors, journal, and citation graph.

Creatinine Paradox in CRRT: Higher Levels, Lower Mortality - A MIMIC-IV Validation Study.

Blood purification·2026

Machine learning-based identification of key genes underlying sex differences in hepatocellular carcinoma and targeted drug screening.

Biomedical reports·2026

Sex as an effect modifier in the association between screen time and depression among US adults with trouble sleeping: A cross-sectional study from NHANES 2005-2018.

Medicine·2026

Nonlinear association between physical activity and bone mineral density in adolescents.

Pediatric research·2026

Association of dietary n-3 and n-6 polyunsaturated fatty acid intake and n-6/n-3 ratio with high-frequency hearing loss: A cross-sectional study.

Medicine·2026

Association between serum osmolality and 30-day all-cause mortality in patients with acute pancreatitis: A retrospective analysis of the MIMIC-IV database.

The American journal of the medical sciences·2026

See all related articles